Anaphylactic Reactions to Oligosaccharides in Red Meat: a Syndrome in Evolution

Clinical and Molecular Allergy

Guha Krishnaswamy¹  Seif Atyia¹  Andromeda Nauli²  Scott Embry¹  Hana Saleh¹ 

[1] Department of Internal Medicine, Division of Allergy and Clinical Immunology, Quillen College of Medicine, East Tennessee State University, P.O. Box 70622, Johnson City, Tennessee 37614-0622, USA;Division of Health Sciences, East Tennessee State University, Johnson City, Tennessee, USA

关键词: Delayed hypersensitivity;    Food allergy;    Anaphylaxis;    Cetuximab;    Oligosaccharides;    Galactosyl-(1,3) galactose;   

Others  :  790584
DOI  :  10.1186/1476-7961-10-5

 received in 2011-11-14, accepted in 2012-03-07,  发布年份 2012

【 摘 要 】

Objective

While most allergic responses to food are directed against protein epitopes and occur within 30 minutes of ingesting the allergen, recent studies suggest that delayed reactions may occur, sometimes mediated by IgE antibodies directed against carbohydrate moieties. The objective of this review is to summarize the clinical features and management of delayed hypersensitivity reactions to mammalian meat mediated by IgE antibodies to galactose-alpha 1,3-galactose (alpha-gal), an oligosaccharide.

Methods

A PubMed search was conducted with MeSH terms: galactosyl-(1,3) galactose, oligosaccharides, cetuximab, allergy/hypersensitivity, and anaphylaxis. Reported cases with alpha-gal-mediated reactions were reviewed. This research study was approved by the Institutional Review Board of East Tennessee State University.

Results

Thirty-two cases of adults presenting with red-meat induced allergy thought to be related to oligosaccharides have been reported in the literature so far, making this a rare and evolving syndrome. Most of these patients demonstrated delayed reactions to beef, as was seen in the case reported by us in this manuscript. IgE specific to alpha-gal was identified in most patients with variable response to skin testing with beef and pork. Inhibition studies in some cases showed that the IgE antibodies to beef were directed towards alpha-gal in the meat rather than the protein. The patients often reported history of tick bites, the significance of which is unclear at present. Reactions to cetuximab, a monoclonal antibody, are mediated by a similar mechanism, with IgE antibodies directed against an alpha-gal moiety incorporated in the drug structure.

Conclusion

Alpha-gal is an oligosaccharide recently incriminated in delayed anaphylactic reactions to mammalian meats such as to beef, pork, and lamb. It appears that anaphylactic reactions to the anti-cancer biological agent, cetuximab, may be linked mechanistically to the same process. More studies are required to understand the underlying molecular basis for these delayed reactions in specific, and their broader implications for host defense in general.

【 授权许可】

   
2012 Saleh et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Lieberman JA, Sicherer SH: Quality of life in food allergy. Curr Opin Allergy Clin Immunol 2011, 11(3):236-242.
• [2]Amrol DJ: Food allergy: an overdiagnosed but underappreciated problem. South Med J 2011, 104(5):308.
• [3]Venter C, Arshad SH: Epidemiology of food allergy. Pediatr Clin North Am 2011, 58(2):327-349. ix
• [4]Boyce JA, Assa'a A, Burks AW, et al.: Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-Sponsored Expert Panel Report. Nutrition 2011, 27(2):253-267.
• [5]Boyce JA, Assa'ad A, Burks AW, et al.: Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010, 126(6 Suppl):S1-S58.
• [6]Koplin JJ, Martin PE, Allen KJ: An update on epidemiology of anaphylaxis in children and adults. Curr Opin Allergy Clin Immunol 2011, 11(5):492-496.
• [7]Sicherer SH: Food allergy. Mt Sinai J Med 2011, 78(5):683-696.
• [8]Lee JK, Vadas P: Anaphylaxis: mechanisms and management. Clin Exp Allergy 2011, 41(7):923-938.
• [9]Keet C: Recognition and management of food-induced anaphylaxis. Pediatr Clin North Am 2011, 58(2):377-388. x
• [10]Jarvinen KM: Food-induced anaphylaxis. Curr Opin Allergy Clin Immunol 2011, 11(3):255-261.
• [11]Food allergies and food intolerances. Both are on the rise--and it's important to know the difference Harv Womens Health Watch 2011, 18(9):4-6.
• [12]Siles RI, Hsieh FH: Allergy blood testing: a practical guide for clinicians. Cleve Clin J Med 2011, 78(9):585-592.
• [13]Kurowski K, Boxer RW: Food allergies: detection and management. Am Fam Physician 2008, 77(12):1678-1686.
• [14]Commins SP, Platts-Mills TA: Allergenicity of carbohydrates and their role in anaphylactic events. Curr Allergy Asthma Rep 2010, 10(1):29-33.
• [15]Husain Z, Schwartz RA: Peanut allergy: an increasingly common life-threatening disorder. J Am Acad Dermatol 2011, 66(1):136-143.
• [16]Ho MH, Wong WH, Heine RG, et al.: Early clinical predictors of remission of peanut allergy in children. J Allergy Clin Immunol 2008, 121(3):731-736.
• [17]Sicherer SH, Munoz-Furlong A, Sampson HA: Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study. J Allergy Clin Immunol 2003, 112(6):1203-1207.
• [18]Jacquenet S, Moneret-Vautrin DA, Bihain BE: Mammalian meat-induced anaphylaxis: clinical relevance of anti-galactose-alpha-1,3-galactose IgE confirmed by means of skin tests to cetuximab. J Allergy Clin Immunol 2009, 124(3):603-605.
• [19]Orhan F, Sekerel BE: Beef allergy: a review of 12 cases. Allergy 2003, 58(2):127-131.
• [20]Theler B, Brockow K, Ballmer-Weber BK: Clinical presentation and diagnosis of meat allergy in Switzerland and Southern Germany. Swiss Med Wkly 2009, 139(17-18):264-270.
• [21]Kim JH, An S, Kim JE, et al.: Beef-induced anaphylaxis confirmed by the basophil activation test. Allergy Asthma Immunol Res 2010, 2(3):206-208.
• [22]Fuentes MM, Palacios R, Garces MM, Caballero ML, Moneo I: Isolation and characterization of a heat-resistant beef allergen: myoglobin. Allergy 2004, 59(3):327-331.
• [23]Mamikoglu B: Beef, pork, and milk allergy (cross reactivity with each other and pet allergies). Otolaryngol Head Neck Surg 2005, 133(4):534-537.
• [24]Eigenmann PA: Anaphylaxis to cow's milk and beef meat proteins. Ann Allergy Asthma Immunol 2002, 89(6 Suppl 1):61-64.
• [25]Martelli A, De CA, Corvo M, Restani P, Fiocchi A: Beef allergy in children with cow's milk allergy; cow's milk allergy in children with beef allergy. Ann Allergy Asthma Immunol 2002, 89(6 Suppl 1):38-43.
• [26]Werfel SJ, Cooke SK, Sampson HA: Clinical reactivity to beef in children allergic to cow's milk. J Allergy Clin Immunol 1997, 99(3):293-300.
• [27]Fuentes AV, Sanchez MI, Perez MA, Baeza ML, de Barrio FM: Allergy to mammal's meat in adult life: immunologic and follow-up study. J Investig Allergol Clin Immunol 2005, 15(3):228-231.
• [28]Restani P, Beretta B, Fiocchi A, Ballabio C, Galli CL: Cross-reactivity between mammalian proteins. Ann Allergy Asthma Immunol 2002, 89(6 Suppl 1):11-15.
• [29]Vicente-Serrano J, Caballero ML, Rodriguez-Perez R, et al.: Sensitization to serum albumins in children allergic to cow's milk and epithelia. Pediatr Allergy Immunol 2007, 18(6):503-507.
• [30]Restani P, Ballabio C, Tripodi S, Fiocchi A: Meat allergy. Curr Opin Allergy Clin Immunol 2009, 9(3):265-269.
• [31]San-Juan S, Lezaun A, Caballero ML, Moneo I: Occupational allergy to raw beef due to cross-reactivity with dog epithelium. Allergy 2005, 60(6):839-840.
• [32]Savi E, Rossi A, Incorvaia C: Cat-pork syndrome: a case report with a thee years follow-up. Eur Ann Allergy Clin Immunol 2006, 38(10):366-368.
• [33]Drouet M, Sabbah A, Le SJ, et al.: Fatal anaphylaxis after eating wild boar meat in a patient with pork-cat syndrome. Allerg Immunol (Paris) 2001, 33(4):163-165.
• [34]Couturier P, Basset-Stheme S, Sainte-Laudy J: [Pork-cat syndrome in a 16-month-old child]. Allerg Immunol (Paris) 1999, 31(2):60.
• [35]Drouet M, Sabbah A: The pork/cat syndrome or crossed reactivity between cat epithelia and pork meat. Monogr Allergy 1996, 32:164-173.
• [36]Drouet M, Lauret MG, Sabbah A: [The pork-cat syndrome: effect of sensitization to cats on sensitization to pork meat. Apropos of a case]. Allerg Immunol (Paris) 1994, 26(8):305-306.
• [37]Drouet M, Lauret MG, Sabbah A: [The pork-cat syndrome: effect of sensitivity to cats on that to pork meat. Based on an observation]. Allerg Immunol (Paris) 1994, 26(7):261-262.
• [38]Sabbah A, Rousseau C, Lauret MG, Drouet M: The pork-cat syndrome: RAST inhibition test with Feld One. Allerg Immunol (Paris) 1994, 26(7):259-260.
• [39]Drouet M, Boutet S, Lauret MG, et al.: The pork-cat syndrome or crossed allergy between pork meat and cat epithelia (1). Allerg Immunol (Paris) 1994, 26(5):166-168. 171-172
• [40]Miller CW, Guha B, Krishnaswamy G: Exercise-induced anaphylaxis: a serious but preventable disorder. Phys Sportsmed 2008, 36(1):87-94.
• [41]Biedermann T, Schopf P, Rueff F, Przybilla B: Exertion-induced anaphylaxis after eating pork and beef. Dtsch Med Wochenschr 1999, 124(15):456-458.
• [42]Fiocchi A, Restani P, Riva E: Beef allergy in children. Nutrition 2000, 16(6):454-457.
• [43]Fiocchi A, Restani P, Bouygue GR, Martelli A: Beef allergy in adults and children. Allergy 2005, 60(1):126.
• [44]Ohmori K, Masuda K, Kawarai S, et al.: Identification of bovine serum albumin as an IgE-reactive beef component in a dog with food hypersensitivity against beef. J Vet Med Sci 2007, 69(8):865-867.
• [45]Han GD, Matsuno M, Ito G, Ikeucht Y, Suzuki A: Meat allergy: investigation of potential allergenic proteins in beef. Biosci Biotechnol Biochem 2000, 64(9):1887-1895.
• [46]Tanabe S, Shibata R, Nishimura T: Hypoallergenic and T cell reactive analogue peptides of bovine serum albumin, the major beef allergen. Mol Immunol 2004, 41(9):885-890.
• [47]Commins SP, Platts-Mills TA: Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant. J Allergy Clin Immunol 2009, 124(4):652-657.
• [48]Commins SP, Satinover SM, Hosen J, et al.: Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2009, 123(2):426-433.
• [49]Macher BA, Galili U: The Galalpha1, 3Galbeta1, 4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 2008, 1780(2):75-88.
• [50]Christiane Y, Aghayan M, Emonard H, et al.: Galactose alpha 1-3 galactose and anti-alpha galactose antibody in normal and pathological pregnancies. Placenta 1992, 13(5):475-487.
• [51]Chung CH, Mirakhur B, Chan E, et al.: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008, 358(11):1109-1117.
• [52]Nunez R, Carballada F, Gonzalez-Quintela A, et al.: Delayed mammalian meat-induced anaphylaxis due to galactose-alpha-1,3-galactose in 5 European patients. J Allergy Clin Immunol 2011, 128(5):1122-1124.
• [53]Van Nunen SA, O'Connor KS, Clarke LR, Boyle RX, Fernando SL: An association between tick bite reactions and red meat allergy in humans. Med J Aust 2009, 190(9):510-511.
• [54]Gronlund H, Adedoyin J, Commins SP, Platts-Mills TA, van HM: The carbohydrate galactose-alpha-1,3-galactose is a major IgE-binding epitope on cat IgA. J Allergy Clin Immunol 2009, 123(5):1189-1191.
• [55]Arkestal K, Sibanda E, Thors C, et al.: Impaired allergy diagnostics among parasite-infected patients caused by IgE antibodies to the carbohydrate epitope galactose-alpha 1,3-galactose. J Allergy Clin Immunol 2011, 127(4):1024-1028.
• [56]Hamadeh RM, Jarvis GA, Zhou P, Cotleur AC, Griffiss JM: Bacterial enzymes can add galactose alpha 1,3 to human erythrocytes and creates a senescence-associated epitope. Infect Immun 1996, 64(2):528-534.
• [57]Khan BQ, Kemp SF: Pathophysiology of anaphylaxis. Curr Opin Allergy Clin Immunol 2011, 11(4):319-325.
• [58]Krishnaswamy G, Ajitawi O, Chi DS: The human mast cell: an overview. Methods Mol Biol 2006, 315:13-34.
• [59]Cetuximab approved by FDA for treatment of head and neck squamous cell cancer Cancer Biol Ther 2006, 5(4):340-342.
• [60]Wong SF: Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005, 27(6):684-694.
• [61]Blick SK, Scott LJ: Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007, 67(17):2585-2607.
• [62]Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ: Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000, 89(1):74-82.
• [63]Baselga J, Pfister D, Cooper MR, et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000, 18(4):904-914.
• [64]Maubec E, Petrow P, Scheer-Senyarich I, et al.: Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011, 29(25):3419-3426.
• [65]Saltz LB, Meropol NJ, Loehrer PJ Sr, et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22(7):1201-1208.
• [66]Argiris A, Feinstein TM, Wang L, et al.: Invest New Drugs: phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. 2011.
• [67]Patel D, Guo X, Ng S, et al.: IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies 2010, 19(4):89-99.
• [68]O'Neil BH, Allen R, Spigel DR, et al.: High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007, 25(24):3644-3648.
• [69]Patel DD, Goldberg RM: Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park) 2006, 20(11):1373-1382.
• [70]Chung CH, O'Neil BH: Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors. Oncology (Williston Park) 2009, 23(2 Suppl 1):14-17.
• [71]George TJ Jr, Laplant KD, Walden EO, et al.: Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. J Support Oncol 2010, 8(2):72-77.
• [72]Chung CH: Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008, 13(6):725-732.
• [73]Saif MW, Syrigos KI, Hotchkiss S, et al.: Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2009, 65(1):107-112.
• [74]Commins SP, James HR, Kelly LA, et al.: The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2011, 127(5):1286-1293.
• [75]Chalaire KC, Kim TK, Garcia-Rodriguez H, Mulenga A: Amblyomma americanum (L.) (Acari: Ixodidae) tick salivary gland serine protease inhibitor (serpin) 6 is secreted into tick saliva during tick feeding. J Exp Biol 2011, 214(Pt 4):665-673.
• [76]Masters EJ, Grigery CN, Masters RW: STARI, or Masters disease: Lone Star tick-vectored Lyme-like illness. Infect Dis Clin North Am 2008, 22(2):361-376. viii
• [77]Bircher AJ, Scherer HK: Drug hypersensitivity reactions: Inconsistency in the use of the classification of immediate and nonimmediate reactions. J Allergy Clin Immunol 2011, 129(1):263-264.
• [78]Thien FC: 3. Drug hypersensitivity. Med J Aust 2006, 185(6):333-338.
• [79]Gruchalla RS: 10. Drug allergy. J Allergy Clin Immunol 2003, 111(2 Suppl):S548-S559.
• [80]Lewis MA, Hendrickson AW, Moynihan TJ: Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin 2011, in press. [Epub ahead of print]
• [81]Salit RB, Bishop MR: The evolving world of tumor lysis syndrome. Oncology (Williston Park) 2011, 25(4):378-380.
• [82]Howard SC, Jones DP, Pui CH: The tumor lysis syndrome. N Engl J Med 2011, 364(19):1844-1854.
• [83]Barbaud A, Granel F, Waton J, Poreaux C: How to manage hypersensitivity reactions to biological agents? Eur J Dermatol 2011, 21(5):667-674.
• [84]Nagy G, Lukacs K, Sziray A, et al.: Adverse events during biological therapy-focusing on dermatological side-effects. Orv Hetil 2011, 152(6):212-220.
• [85]van Bueren JJ, Rispens T, Verploegen S, et al.: Anti-galactose-alpha-1,3-galactose IgE from allergic patients does not bind alpha-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol 2011, 29(7):574-576.
• [86]Heun J, Holen K: Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer 2007, 6(7):529-531.
• [87]Nielsen DL, Pfeiffer P, Jensen BV: Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab. Ann Oncol 2009, 20(4):798.
• [88]Power DG, Shah MA, Asmis TR, Garcia JJ, Kemeny NE: Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Invest New Drugs 2010, 28(3):353-360.
• [89]Restani P, Ballabio C, Cattaneo A, et al.: Characterization of bovine serum albumin epitopes and their role in allergic reactions. Allergy 2004, 59(Suppl 78):21-24.
• [90]Fiocchi A, Restani P, Riva E, et al.: Meat allergy: II-Effects of food processing and enzymatic digestion on the allergenicity of bovine and ovine meats. J Am Coll Nutr 1995, 14(3):245-250.
• [91]Fiocchi A, Restani P, Riva E, et al.: Heat treatment modifies the allergenicity of beef and bovine serum albumin. Allergy 1998, 53(8):798-802.
• [92]Han GD, Matsuno M, Ikeuchi Y, Suzuki A: Effects of heat and high-pressure treatments on antigenicity of beef extract. Biosci Biotechnol Biochem 2002, 66(1):202-205.
• [93]Jackson J, Beveridge I, Chilton NB, Andrews RH: Distributions of the paralysis ticks Ixodes cornuatus and Ixodes holocyclus in south-eastern Australia. Aust Vet J 2007, 85(10):420-424.
• [94]Hall-Mendelin S, Craig SB, Hall RA, et al.: Tick paralysis in Australia caused by Ixodes holocyclus Neumann. Ann Trop Med Parasitol 2011, 105(2):95-106.
• [95]Campbell F, Atwell R, Fenning A, Hoey A, Brown L: Cardiovascular effects of the toxin(s) of the Australian paralysis tick, Ixodes holocyclus, in the rat. Toxicon 2004, 43(7):743-750.
• [96]Campbell FE, Atwell RB: Long QT syndrome in dogs with tick toxicity (Ixodes holocyclus). Aust Vet J 2002, 80(10):611-616.
• [97]Miller MK: Massive tick (Ixodes holocyclus) infestation with delayed facial-nerve palsy. Med J Aust 2002, 176(6):264-265.
• [98]Grattan-Smith PJ, Morris JG, Johnston HM, et al.: Clinical and neurophysiological features of tick paralysis. Brain 1997, 120(Pt 11):1975-1987.
• [99]Drover VA, Ajmal M, Nassir F, et al.: CD36 deficiency impairs intestinal lipid secretion and clearance of chylomicrons from the blood. J Clin Invest 2005, 115(5):1290-1297.
• [100]Nauli AM, Zheng S, Yang Q, et al.: Intestinal alkaline phosphatase release is not associated with chylomicron formation. Am J Physiol Gastrointest Liver Physiol 2003, 284(4):G583-G587.
• [101]Nauli AM, Nassir F, Zheng S, et al.: CD36 is important for chylomicron formation and secretion and may mediate cholesterol uptake in the proximal intestine. Gastroenterology 2006, 131(4):1197-1207.
• [102]Porter CJ, Trevaskis NL, Charman WN: Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007, 6(3):231-248.
• [103]Miller CW, Krishnaswamy N, Johnston C, Krishnaswamy G: Severe asthma and the omalizumab option. Clin Mol Allergy 2008, 6:4. BioMed Central Full Text